Medical/Pharmaceuticals

RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study

Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity  Opaganib's unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect agai...

2021-06-28 19:00 11248

The Third Asia Pacific Psychiatry Symposium Takes Place

SHANGHAI, June 28, 2021 /PRNewswire/ -- The global COVID-19 pandemic poses a serious threat to physical health and has wide-ranging implications for mental health worldwide. At the third Asia Pacific Psychiatry Symposium, held online on June 26, more than 1,000 psychiatrists, general practitioners...

2021-06-28 15:51 2351

Active8me Announces New Health Tech Partnership

MANILA, Philippines, June 28, 2021 /PRNewswire/ -- Award-winning health and wellness platform Active8me today announced a partnership with mWell to deliver unprecedented online health care services inthe Philippines. Under the collaboration, Filipinos will have access to online doctor consult...

2021-06-28 12:00 1544

With the Second-Generation transcatheter aortic valve replacement system approved for marketing, Peijia Medical leads China into the "Retrievable Era" using TAVR products

SUZHOU, China, June 28, 2021 /PRNewswire/ -- The TaurusElite® Transcatheter Aortic Valve Replacement System (hereinafter referred to as "TaurusElite®") developed by Peijia Medical (9996.HK) is approved for marketing by the National Medical Products Administration (NMPA) inJune 2021 (Reg. No. GXZZ...

2021-06-28 11:15 8164

Qbiotics concludes successful $85 million capital raise

* Capital raise nets $85 million from Existing Shareholders, Existing Institutional Investors, and cornerstone investor TDM Growth Partners. * Funding to enable human clinical development of the Company's anticancer drug candidate tigilanol tiglate and its wound healing drug candidate EBC-1013...

2021-06-28 09:36 2081

CStone announces positive registrational study of GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer

* Key efficacy data for GAVRETO showed deep and durable anti-tumor activity in Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) * In March 2021, GAVRETO was approved by the National Medical Products Administration (NMPA) ofChina for the treatment of patie...

2021-06-28 08:05 4373

Innovent Announces the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab biosimilar injection) as First-Line Therapy for People with Hepatocellular Carcinoma

SAN FRANCISCO and SUZHOU, China, June 28, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-06-28 08:00 4705

BIO Asia-Taiwan 2021 to Go Ahead in 'All Online' Format

TAIPEI, June 28, 2021 /PRNewswire/ -- In response to ongoing restrictions in Taiwan due to the COVID-19 pandemic, BIO Asia-Taiwan 2021 will be held as scheduled fromJuly 21-25 but in an all-online format, with activities including the Conference, Exhibition, BIO's One-on-one Partnering™, Company ...

2021-06-28 07:30 1953

China's Public Health System Primed for Digital Innovation Online/Offline Service Delivery 'Huge Growth Opportunity', says Ping An Co-CEO

HONG KONG and SHANGHAI, June 25, 2021 /PRNewswire/ -- Ping An is investing further in its healthcare ecosystem to meet the growing public healthcare needs inChina, says Jessica Tan, Co-CEO of Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 60...

2021-06-25 21:19 27413

HistoIndex's AI-Based Digital Pathology Indicates Concomitant Histological Improvements in Liver Fat and Fibrosis in Nonalcoholic Steatohepatitis (NASH) Patients Treated with Tropifexor Compared with Placebo

SINGAPORE, June 25, 2021 /PRNewswire/ -- HistoIndex 's Second Harmonic Generation (SHG) stain-free digital pathology platform has shown marked reduction in liver fibrosis (overall, reduction in perisinusoidal fibrosis, as well as regression of fibrous septa) from bas...

2021-06-25 18:30 1983

Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003

HANGZHOU, China, June 25, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative drug development company, announced today that its new Class I innovative drug LNK01003, has been approved by National Medical Products Administration (...

2021-06-25 15:11 3084

GenScript receives "Best Contract Development and Manufacturing Organization Award" in the Korea Bioprocessing Excellence Awards 2021

SINGAPORE, June 25, 2021 /PRNewswire/ -- GenScript receives the "Best Contract Development and Manufacturing Organization Award" on the Korea Bioprocessing Excellence Awards 2021 held on 24th June 2021. GenScript achieve the Best CDMO award for two years in a row.

2021-06-25 10:30 17778

Moving ahead: Copan announces a major rebranding and launches a new website

BRESCIA, Italy, June 25, 2021 /PRNewswire/ -- Time of change for Copan. The Italian preanalytics company announced the completion of an extensive rebranding initiative which includes a new logo and a new website with updated functionalities. The rebranding aims to represent at best the company va...

2021-06-25 08:25 2734

Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Glucagon-like Peptide-1 and Glucagon Receptor Dual Agonist in Overweight or Obese Chinese Participants at the American Diabetes Association's 81st Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...

2021-06-25 08:00 5549

Bridge Biotherapeutics Integrates CDD Vault Collaborative Database Solution into Its R&D Platform to Harmonize Research and Drug Discovery Project Management

- Bridge has been enhancing its research and drug discovery engines by efficiently managing scientific assets on a collaborative database solution - CDD provides a secure research database platform enabling seamless collaboration between drug discovery and development teams that are in different...

2021-06-25 05:57 2017

Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE

NANJING, China, June 24, 2021 /PRNewswire/ -- Triastek, Inc. (Triastek), a global leader in 3D printed pharmaceuticals, has completed its Series B financing, raisingUS$ 50 million (RMB 330 million). This round of investment was co-led by Matrix Partners China and CPE, with participation from S...

2021-06-25 00:26 2662

GenesisCare Expands their MR-guided Radiotherapy Reach with the Purchase of Multiple MRIdian® Systems

Master agreement includes program plans for up to a further 14 systems with immediate expansion in 2 key markets CLEVELAND, June 24, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that GenesisCare has entered into a master purchase agreement for up to 14 MRIdian® MR-Guided The...

2021-06-24 22:33 14186

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

SHENZHEN, China, June 24, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Tucidinostat (also known as Chidamide, Epidaza ®, HBI-8000) monotherapy of relapsed or refractory (R/R) adult T-cell le...

2021-06-24 19:00 2063

Advanced Aesthetic Technologies, Inc. Announces the Treatment of the First Patient in a Pivotal Clinical Trial in China with their Algeness® VL (2.5% Agarose Gel) Filler for the Correction of Moderate to Severe Nasolabial Folds

This new clinical trial is being conducted through their partnership with Lanzhou Biotechnique Development Co., LTD (LanDev) and their parent company China National Biotec Group Co., LTD (CNBG) and will be used to seek marketing approval inChina BROOKLINE, Mass., June 24, 2021 /PRNewswire/ -- Ad...

2021-06-24 18:00 1958

Boan Biotech Publishes Research Results for CEA/CD3 Bispecific Antibody in Antibody Therapeutics

BOSTON, June 24, 2021 /PRNewswire/ -- Luye Pharma Group's subsidiary Boan Biotech recently published research results for its innovative in-house bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) inAntibody Therapeutics. Screensh...

2021-06-24 14:49 2686
1 ... 235236237238239240241 ... 382